Alabama Medicaid GLP-1 Coverage (2026): PDL-Enumerated OSA-Only Zepbound Carve-Out + Off-PDL Cardiac-Criteria Wegovy MACE Exclusion — NO Chronic-Weight-Management Coverage

TL;DR — What Alabama Medicaid Actually Covers

Alabama is a regulatory-exclusion state with two narrow non-weight-loss carve-outs: an in-PDL OSA-only Zepbound footnote and an off-PDL Cardiac-Agents-only Wegovy MACE pathway. Neither pathway covers chronic weight management. Alabama is one of ten non-expansion states, meaning the Medicaid-eligible adult population is concentrated in pregnant women, parents/caretaker relatives at below 18% FPL, the elderly/disabled, and SSI/Plan First categorical eligibles — structurally narrowing the number of Alabamians who could access even the OSA or MACE carve-outs.

Pattern #23 in the 50-state series: PDL-enumerated OSA-only Zepbound + off-PDL Cardiac-Criteria Wegovy

Alabama’s coverage architecture is structurally distinctive across all 23 states documented so far:

The key structural distinctions from prior states:

• vs. Texas (#1): Both use Acentra Health as the pharmacy administrative services contractor and operate statewide FFS with no MCO pharmacy carve-out. Texas’s January 30, 2026 PDL omits Zepbound entirely and has no Wegovy MACE pathway. Alabama goes operationally further: Zepbound is in the Alabama PDL drug class table with a footnote restriction (not absent like Texas), and Alabama has an explicit off-PDL Wegovy MACE Cardiac Agents pathway that Texas does not.
• vs. Kentucky (#21): Both states have OSA-only Zepbound and MACE-only Wegovy carve-outs, reaching a similar de-facto exclusion outcome via different operational mechanisms. Alabama’s Zepbound OSA carve-out is in the PDL drug class table (footnote ^); Kentucky’s is in stand-alone PA criteria PDFs published to the MedImpact portal. Alabama’s Wegovy MACE pathway is in the PA Form 369 Cardiac Agents section; Kentucky’s is in a stand-alone PA criteria PDF. Alabama uses Acentra Health; Kentucky uses MedImpact.
• vs. Ohio (#6): Ohio created a dedicated “Metabolic Modifiers” PDL class (January 7, 2026) to operationalize Wegovy MACE + MASH and Zepbound OSA carve-outs. Alabama has no parallel dedicated class — Zepbound is in Incretin Mimetics with a footnote, and Wegovy is administered through the Cardiac Agents PA section.
• vs. Tennessee (#13): Both are non-expansion states. TennCare moved affirmatively toward chronic-weight- management coverage (Sequence 10-34-25, effective January 26, 2026 — broadest published AOM panel in the series). Alabama has not made a parallel rulemaking change; the Joint Legislative Task Force on Chronic Weight Management is in study-only posture.
• vs. Indiana (#16): Both have a categorical regulatory exclusion + de-facto FDA-label carve-outs. Indiana has a verified EPSDT-specific GLP-1 bulletin (BT2023148); Alabama has no verified EPSDT-specific GLP-1 bulletin in the primary sources reviewed for this analysis.

The canonical regulatory exclusion — Ala. Admin. Code r. 560-X-16-.01(2)(b)

The primary regulatory anchor for Alabama Medicaid’s GLP-1 weight-loss exclusion is Rule 560-X-16-.01 of the Alabama Administrative Code, Chapter 16 (“Pharmaceutical Services”). The rule was verified via direct PDF fetch from medicaid.alabama.gov/documents/9.0_Resources/9.2_Administrative_Code/ 9.2_Adm_Code_Chap_16_Pharmaceutical_Services_7-15-24.pdf on 2026-05-10.

Verbatim from Rule 560-X-16-.01, Section (2):

“(2) In accordance with the Medicaid Drug Amendments contained in the Omnibus Budget Reconciliation Act of 1990, (Public Law 101-508), the following shall apply: with the exception of allowable published exclusions, only those drugs manufactured by companies having signed rebate agreements with the Secretary of Health and Human Services are compensable. The exclusions are:

(a) DESI and IRS drugs which may be restricted in accordance with Section 1927(d)(2) of the Social Security Act

(b) Agents when used for anorexia, weight loss, or weight gain except for those specified by the Alabama Medicaid Agency. Selective covered outpatient drugs for all eligible beneficiaries will be covered as listed on the state’s website.

(c) Agents when used to promote fertility except for those specified by the Alabama Medicaid Agency. Selective covered outpatient drugs for all eligible beneficiaries will be covered as listed on the state’s website.

(d) Agents when used for the symptomatic relief of cough and cold.

(e) Prescription vitamin and mineral products, except prenatal vitamins and fluoride preparations and others as specified by the Alabama Medicaid Agency. Selective covered outpatient drugs for all eligible beneficiaries will be covered as listed on the state’s website.

(f) Selective non-prescription covered outpatient drugs for all eligible beneficiaries will be covered as listed on the state’s website.

(g) Covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated test or monitoring services be purchased exclusively from the manufacturer or its designee.”

The operative phrase is in subsection (2)(b): “Agents when used for anorexia, weight loss, or weight gain except for those specified by the Alabama Medicaid Agency. Selective covered outpatient drugs for all eligible beneficiaries will be covered as listed on the state’s website.”

This “except for those specified” clause is the regulatory mechanism that enables both carve-outs: Zepbound is “specified” for OSA via the April 1, 2026 PDL footnote, and Wegovy is “specified” for MACE via the PA Form 369 Cardiac Agents section. The state-website-designation mechanism — “will be covered as listed on the state’s website” — is how the AMA operationalizes the exception without promulgating a formal rulemaking amendment for each new drug indication.

This rule is subordinate to the federal optional-exclusion authority at 42 U.S.C. § 1396r-8(d)(2)(A):

“(2) The following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted: (A) Agents when used for anorexia, weight loss, or weight gain.”

The federal authority is permissive (“may be excluded”); the state rule is the operative exclusion. Amending the state exclusion requires a rulemaking docket through the AMA Office of General Counsel and legislative review through the Joint Committee on Administrative Regulation Review — not a quarterly PDL update.

Alabama Medicaid PDL (April 1, 2026) — Incretin Mimetics class verbatim

The operative PDL is the Alabama Medicaid Agency Preferred Drug List by Therapeutic Category, effective 04/01/2026 (direct PDF: medicaid.alabama.gov/documents/4.0_Programs/4.3_Pharmacy-DME/ 4.3.7_Preferred_Drug_List/4.3.7_PDL_Thera_3-16-26.pdf; publication date March 16, 2026; effective April 1, 2026; verified 2026-05-10). The PDL document header states verbatim:

“ALABAMA MEDICAID AGENCY PREFERRED DRUG LIST BY THERAPEUTIC CATEGORY

As a result of legislation passed by the Alabama State Legislature in June 2003, the Alabama Medicaid Agency implemented a mandatory Preferred Drug List, effective October 1, 2003. Brand preferred drugs, generics (some exceptions apply) and over-the-counter (OTC) drugs covered by Medicaid are available without prior approval. If a non-preferred drug is ordered, the practitioner will need to obtain prior authorization (PA). Drugs that are ‘preferred with clinical criteria’ will also require a prior authorization request be submitted. If approval is given to dispense the requested drug, an authorization number will be provided. Antipsychotic and HIV/AIDS drugs are exempt from this requirement.”

The Diabetic Agents > Incretin Mimetics section appears on page 2 of the therapeutic-category PDL. Verbatim:

“Diabetic Agents
  [Alpha-Glucosidase Inhibitors, Amylinomimetics, Biguanides, DPP-4 Inhibitors omitted for brevity]
  Incretin Mimetics
    Byetta*^CC     Mounjaro^CC
    Ozempic^CC     Rybelsus^CC
    Trulicity^CC     Victoza*^CC
    Zepbound ^ ^CC
    All covered generics (generic liraglutide and exenatide require a PA)”

The superscript CC notation means preferred with clinical criteria — a PA is required. The ^ symbol next to Zepbound refers to the PDL footnote that appears on every page of both the therapeutic-category and alphabetical PDL documents.

Verified absence from the April 1, 2026 AMA PDL (both therapeutic-category and alphabetical versions, verified by exhaustive text extraction): Wegovy, Saxenda, Qsymia, Contrave, phentermine (as a stand-alone obesity agent), orlistat, Xenical — zero occurrences. There is no “Anti-Obesity Drugs,” “Weight Management Agents,” or “Metabolic Modifiers” PDL class in Alabama Medicaid, unlike Massachusetts (Pattern #15), Maryland (Pattern #17), Minnesota (Pattern #20), Missouri (Pattern #22), or Ohio’s January 7, 2026 addition (Pattern #6).

The in-PDL Zepbound OSA-only footnote — first in-PDL instance in the 23-state series

The footnote marked by ^ next to Zepbound appears on every page of both the therapeutic-category and alphabetical versions of the April 1, 2026 PDL. Verbatim from the footnote:

“^ Zepbound is preferred with clinical criteria for its Obstructive Sleep Apnea (OSA) with obesity indication. Zepbound is non-covered for weight reduction without OSA.”

This is the canonical AMA-authored statement of Zepbound’s coverage scope. The article writer and any patient reading this should note the explicit language: “Zepbound is non-covered for weight reduction without OSA.” There is no ambiguity in the PDL text.

The Zepbound OSA pathway in the PA Form 369 Criteria Instructions (Antidiabetic Agents/Incretin Mimetics section, page 21, effective August 15, 2025) specifies the clinical criteria verbatim:

“For OSA indications for incretin mimetics, patient must be ≥18 years of age with moderate to severe obstructive sleep apnea (apnea-hypopnea index [AHI] ≥15) and obesity (BMI ≥30 kg/m²) with no diagnosis of diabetes. The patient has been counseled to continue a reduced-calorie diet and increased physical activity and is not taking this medication in combination with another GLP-1 agonist. Stable therapy does not apply.”

The five operative gates for the Zepbound OSA pathway:

Alabama’s Zepbound OSA pathway is less restrictive than Kentucky’s on two criteria (no CPAP trial, no sleep specialist), while both states reach the same de-facto conclusion: neither covers Zepbound for chronic weight management. The architectural distinction — in-PDL footnote (AL) vs. off-PDL stand-alone PA PDF (KY) — makes Alabama’s Zepbound OSA eligibility more visible to prescribers at the point of PDL lookup, while Kentucky’s requires a separate document search.

The “stable therapy does not apply” clause prevents the 60-day-stable-therapy bypass of the PA requirement that exists for other drug classes. Every Zepbound OSA request is a fresh PA submission with clinical criteria documentation.

Clinical significance of “no diagnosis of diabetes”: Patients with both T2D and OSA are routed to the GLP-1 RA T2D class (Mounjaro, Ozempic, etc.) rather than the Zepbound OSA pathway. Mounjaro covers the T2D indication and may incidentally reduce OSA severity — but Alabama Medicaid does not cover Mounjaro for its OSA FDA label. The OSA pathway is exclusive to non-diabetic patients.

Wegovy administered through the Cardiac Agents PA section — NOT a GLP-1 or Anti-Obesity class

Wegovy’s coverage in Alabama Medicaid operates exclusively through the PA Form 369 Cardiac Agents section. Wegovy does not appear on the AMA PDL drug class table — not in Incretin Mimetics, not in a dedicated Anti-Obesity class, not anywhere. This operational architecture is unique in the 23-state series and requires a specific navigational note for prescribers: the PA Form 369 Cardiac Agents section is where the Wegovy request must be filed.

The PA Form 369 Criteria Instructions (effective August 15, 2025), Cardiac Agents section (pages 31–32), states verbatim:

“Cardiac Agents

Appropriate Diagnosis
• The patient must have an appropriate diagnosis supported by documentation in the patient record.

Prior Treatment Trials
• The patient must also have failed 30-day treatment trials with at least two prescribed and preferred cardiac agents in this class, either generic, OTC, or brand, within the past 6 months or have a documented allergy or contraindication to all preferred agents in this class.

• To meet these prior usage requirements, drugs within this specific classification must be judged against others in the same class (AHFS specific).

⇒ For Ranexa®, in lieu of prior usage requirements, approval may be obtained for adjunctive therapy to a current antianginal drug.

⇒ For Corlanor®, previous beta-blocker usage or contraindication to beta-blocker therapy is required.

⇒ Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight. Requests must include documentation to support the FDA approved indication related to cardiovascular disease.
      • For Wegovy® cardiovascular renewals, prescriber must provide documentation of member weight records (dated within the last 90 days), member requires Wegovy® for cardiovascular risk reduction and the benefit of cardiovascular risk reduction outweighs the risk associated with use of GLP-1 agents, and medical records document appropriate diagnosis.”

The PA approval timeframes section states verbatim:

“PA Approval Timeframes
• Approval may be given for up to 12 months, with the exception of Wegovy® which may be given for 6 months.”

Four implications of the Cardiac Agents Wegovy pathway:

1. Wegovy is a non-preferred Cardiac Agent, not a PDL drug. There is no Wegovy entry in the Alabama Medicaid PDL drug class table. Access is exclusively through a PA submission to Acentra Health citing the PA Form 369 Cardiac Agents criteria.
2. The MACE indication language mirrors the FDA SELECT trial label exactly. “Established cardiovascular disease and either obesity or overweight” — this is the SELECT trial enrollment criterion, not a general obesity + cardiovascular-risk pathway. The patient must have documented established CVD (prior MI, stroke, or peripheral artery disease), not merely elevated cardiovascular risk factors.
3. 6-month approval vs. 12-month standard. All other Cardiac Agents receive up to 12-month PA approval. Wegovy’s 6-month cap creates a more frequent renewal burden. Each renewal requires weight records (within 90 days), cardiovascular-risk-benefit documentation, and appropriate diagnosis records.
4. No Anti-Obesity class for Wegovy to fall back on. Unlike Massachusetts (Anchor #15) or Minnesota (Anchor #20), Alabama has no “Anti-Obesity Agents” or “Weight Management Agents” PDL class. Wegovy cannot be accessed via any alternative PDL class pathway.

We do not cite the Real Chemistry “Yes coverage” classification — why it is misleading

The Real Chemistry analysis observed Wegovy reimbursement in Alabama Medicaid claims data and classified Alabama as a “Yes coverage” state. That observed reimbursement reflects FDA-label MACE-indicated Wegovy prescriptions administered through the PA Form 369 Cardiac Agents section — not coverage of chronic weight management.

The operative AMA policy is unambiguous (PA Form 369 verbatim, quoted above): “Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.” The cardiovascular indication is the sole documented pathway. The “obesity or overweight” qualifier in the MACE label does not create a weight-management coverage pathway — it is a patient-population descriptor for the SELECT trial, not an obesity-treatment indication.

The Real Chemistry analysis also cited $43.1 million in Alabama Medicaid GLP-1 spending over the prior 12 months with 107% year-over-year growth. This figure encompasses T2D-indicated GLP-1s (Ozempic, Trulicity, Mounjaro, Victoza, Byetta) AND Wegovy MACE coverage for patients with obesity-related diagnoses — it is not obesity-only spending.

The KFF January 2026 tracker classifies Alabama as a non-coverage state. KFF identified 13 states covering GLP-1s for the obesity indication as of January 2026; Alabama is not among them. We use the KFF tracker as our secondary classification anchor, cross-verified against the AMA PDL and PA Form 369 as primary sources.

Patients reading secondary-source summaries that characterize Alabama as a Wegovy-coverage state should NOT assume coverage for weight loss. The operative AMA policy documents — the April 1, 2026 PDL and the PA Form 369 Criteria Instructions effective August 15, 2025 — are the authoritative sources.

Acentra Health PBM — same contractor as Texas, distinct from every other state in the series

Alabama Medicaid’s pharmacy administrative services contractor is Acentra Health (formerly Kepro), headquartered at P.O. Box 3570, Auburn, AL 36831. Acentra performs:

• Prior-authorization adjudication for all PDL classes
• Operation of the published provider portal at almedicaid.acentra.com
• Quarterly Pharmacy Newsletter publication (Alabama Medicaid Pharmacist)
• Staff-physician review of medical-justification PA requests

The December 8, 2025 AMA Provider ALERT (ID 16674) confirms the Acentra Health PA submission address verbatim:

“Providers requesting PAs by mail or fax should send requests to:
Acentra Health
Medicaid Pharmacy Administrative Services
P.O. Box 3570, Auburn, AL 36831
Fax: 1-800-748-0116
Phone: 1-800-748-0130”

Electronic PA submission is available at medicaid.alabama.gov via the PA Form 369 link in the Forms Library (Section 9.4.13). The NDC drug-coverage lookup is at medicaid.alabamaservices.org/alportal/NDC%20Look%20Up/.

Acentra Health is also Texas Medicaid’s pharmacy administrative services contractor (Pattern #1). The structural similarity between Alabama and Texas at the PBM-contractor level is the closest analog in the series. However, the two states reach materially different operational outcomes: Texas’s January 30, 2026 Acentra PDL Criteria Guide omits Zepbound entirely; Alabama’s Acentra-administered PDL lists Zepbound with the OSA-only footnote restriction. And Texas has no documented Wegovy MACE Cardiac Agents pathway equivalent to Alabama’s PA Form 369 section.

Gainwell Technologies is the Alabama Medicaid claims fiscal agent (interChange MMIS), responsible for claims processing and payment. Gainwell is distinct from Acentra’s PA-adjudication role. This Gainwell/Acentra split-contractor architecture parallels Missouri (Anchor #22, Gainwell PDL + Conduent SmartPA) but is structured differently: Alabama’s Gainwell is claims-fiscal-agent only, not a PDL-classification contractor.

Magellan Medicaid Administration is NOT the Alabama Medicaid PBM. Magellan was acquired by Prime Therapeutics in 2022; Alabama transitioned to Acentra Health for pharmacy administrative services. Providers and prescribers referencing older Alabama Medicaid PA guide materials that name Magellan should update their workflows to the Acentra Health portal.

ACHN care-coordination architecture — no MCO pharmacy carve-out

Alabama Medicaid operates through the Alabama Coordinated Health Network (ACHN), a seven-region care-coordination delivery system. ACHN provides care coordination, Health Homes, the Maternity Program, and Plan First family planning services. It does NOT administer pharmacy benefits and does NOT carve out pharmacy benefits to MCOs.

This is structurally the most important distinction between Alabama and 10+ other states in this series:

Because Alabama Medicaid is statewide FFS with no MCO pharmacy carve-out, there are no plan-level deviations from the AMA PDL and PA Form 369 criteria. The single statewide formulary applies uniformly to all Alabama Medicaid recipients. Prescribers and pharmacies interact with one PA adjudication system (Acentra Health) through one portal (almedicaid.acentra.com). This is architecturally simpler than the 22 prior states in the series, most of which have MCO-administered or MCO-delegated pharmacy benefits requiring plan-level verification.

T2D vs. weight-loss GLP-1 coverage — the operative distinction

Alabama Medicaid does cover GLP-1 receptor agonists for type 2 diabetes. The April 1, 2026 PDL lists seven Incretin Mimetic agents as preferred with clinical criteria for T2D: Byetta, Mounjaro, Ozempic, Rybelsus, Trulicity, Victoza, and Zepbound (OSA only). The T2D PA criteria in the PA Form 369 Antidiabetic Agents/Incretin Mimetics section require:

“The patient must also have failed 30-day treatment trials with at least two prescribed and preferred antidiabetic agents, either generic, OTC, or brand, within the past 12 months, or have a documented allergy or contraindication to all preferred agents in this class.

Preferred agents in the Incretin Mimetic class are ‘preferred with clinical criteria’ and must meet specified clinical criteria to include FDA approved indications and prior therapy trials.

[Stable therapy:] Approval may be given for those who have documented stable therapy on the requested medication for 60 consecutive days or greater.

[PA Approval Timeframes:] Approval may be given for up to 12 months.”

This two-step prior-therapy standard is less restrictive than Wisconsin’s 2-lifetime-attempts cap (Anchor #19) and more permissive than Illinois’s prohibition on GLP-1s entirely (Anchor #5). For T2D patients who have already tried two preferred antidiabetic agents (or can document allergy/ contraindication), access to Ozempic, Mounjaro, or other preferred Incretin Mimetics is available under standard T2D PA criteria.

The critical distinction: Mounjaro (tirzepatide for T2D) ≠ Zepbound (tirzepatide for OSA). Both contain tirzepatide, but they are separate FDA-approved products with different indications and are treated as separate drugs on the Alabama Medicaid PDL. Mounjaro is preferred-CC for T2D (added to the PDL effective January 1, 2026 per the December 8, 2025 AMA Provider ALERT). Zepbound is preferred-CC for OSA with obesity only. A diabetic patient with OSA would be covered for Mounjaro under T2D criteria, not Zepbound under OSA criteria.

HJR162 and SJR60 — study resolutions, not coverage mandates

The 2026 Alabama Regular Session produced two GLP-1-related legislative actions. Both are non-binding study resolutions, not coverage mandates.

HJR162 (House Joint Resolution 162, 2026 Alabama Regular Session) — status as of 2026-05-10: Passed House March 5, 2026; delivered to the Governor. Summary per LegiScan and secondary-source aggregation (LegiScan direct fetch returned 403):

Resolution encouraging the Alabama Medicaid Agency to evaluate the overall costs of GLP-1 medications and report its findings to the Legislature.

SJR60 (Senate Joint Resolution 60, 2026 Alabama Regular Session) — status as of 2026-05-10: Introduced February 25, 2026; pending in Senate Rules Committee with 0% progression.

Companion to HJR162 — resolution encouraging the Alabama Medicaid Agency to evaluate the overall costs of GLP-1 medications and report its findings to the Legislature.

What HJR162 and SJR60 do NOT do:

• Neither modifies Ala. Admin. Code r. 560-X-16-.01(2)(b), the categorical weight-loss-drug exclusion rule.
• Neither amends the Alabama Medicaid PDL to add Wegovy, Saxenda, or Zepbound for chronic weight management.
• Neither directs AMA to initiate a rulemaking proceeding to add chronic-weight-management GLP-1 coverage.
• Neither creates a funding source for GLP-1 obesity coverage.

These resolutions are more accurately characterized as legislative cost-education directives than as coverage-direction legislation. By contrast, New Jersey’s A3369 (Anchor #11) is a bill that would mandate commercial insurance coverage — a substantively different legislative posture. Alabama’s HJR162/SJR60 are weaker legislative signals than NJ’s A3369.

The Joint Legislative Task Force on Chronic Weight Management and Type 2 Diabetes, chaired by Rep. Ed Oliver (R-Dadeville), has held public hearings on November 17, 2025 (Dr. Katherine Saunders, NYC obesity-medicine specialist) and December 5, 2024 (William Ashmore, then-SEIB CEO; Richard Embrey, task force member). The December 5, 2024 hearing produced three verbatim quotes from the Alabama Daily News that capture the prevailing fiscal posture:

“This is probably as important as any issue that we deal with in government in terms of money and health.” — Rep. Ed Oliver, R-Dadeville (Task Force Chair), December 5, 2024

“The GLP-1 (drugs) are just so much more expensive than everywhere else.” — William Ashmore, SEIB CEO, December 2024

“It’s hard to make right now a business case for covering these drugs for obesity.” — Richard Embrey, task force member, December 2024

Ashmore also cited a 10-fold SEIB GLP-1 spending increase: “Back in 2018, the GLP-1 drugs, we spent $3.5 million; this past year, we spent $35.5 million.” That figure is SEIB (state employee plan, diabetes coverage only) — not Alabama Medicaid.

The task force’s deliberative posture and the HJR162/SJR60 cost-evaluation framework together suggest that any change to Alabama Medicaid GLP-1 coverage would require: (1) AMA completing its cost evaluation per the resolution directive; (2) the task force recommending coverage expansion to the Legislature; (3) the Legislature appropriating funds or directing rulemaking; and (4) AMA promulgating a rule amendment to Ala. Admin. Code r. 560-X-16-.01(2)(b). None of these steps have occurred as of 2026-05-10.

Stephanie Azar SEIB CEO transition — outside Medicaid scope

The Alabama State Employees’ Insurance Board (SEIB) is a separately governed state-employee health plan and is NOT Alabama Medicaid. SEIB administers health insurance for approximately 90,000 active and retired state employees and their dependents. SEIB GLP-1 coverage as of December 2024 is limited to diabetes (per Ashmore’s December 2024 task force testimony). There is no SEIB GLP-1 coverage for weight loss.

The June 18, 2025 transition is notable for the direct cabinet-to-board personnel overlap. Per the Alabama Daily News reporting (June 18, 2025):

“The Alabama State Employees’ Insurance Board unanimously voted to elect Stephanie Azar as new CEO. She has served as Alabama Medicaid Agency commissioner since 2012.”

Azar: “It’s very humbling to me to be honest with you. I’m just going to give it my all, do the best I can to uphold SEIB’s mission and vision.”

Gov. Ivey: “Stephanie Azar has been an instrumental part of my administration, and I could not be prouder to see her selected as the new CEO.”

“Azar will not assume the role until ‘Gov. Kay Ivey selects a new Medicaid commissioner and there is a transition period.’”

As of 2026-05-10, Azar’s transition from AMA Commissioner to SEIB CEO is pending Governor Ivey’s selection of a new Medicaid Commissioner. This direct AMA-Commissioner-to-SEIB-CEO transition is distinctive among the 23 states in this series — the outgoing Medicaid administrator is moving directly into leadership of the state employee health plan that was simultaneously evaluating GLP-1 costs with the Joint Legislative Task Force. The policy implications of that transition are not predictable from primary-source records; we note the transition as documented contextual fact.

Readers should not conflate SEIB coverage (or non-coverage) with Alabama Medicaid GLP-1 policy. They are governed by different boards, different statutes, and different PBMs. A change to SEIB GLP-1 coverage for weight loss would not automatically expand Alabama Medicaid GLP-1 coverage.

Non-expansion state context — 39.2% adult obesity prevalence, 5th highest nationally

Alabama is one of ten non-expansion states as of 2026 — the others being Florida, Georgia, Kansas, Mississippi, South Carolina, Tennessee, Texas, Wisconsin, and Wyoming. The ACA Medicaid expansion (to 138% FPL for all adults) was optional for states under NFIB v. Sebelius (2012), and Alabama has not exercised the expansion option.

Non-expansion status has two direct implications for Alabama Medicaid GLP-1 access:

1. Narrower eligible population. Alabama’s adult Medicaid population is concentrated in pregnant women, parents/caretaker relatives at below 18% FPL, the elderly/disabled, and SSI/Plan First categorical eligibles. Low-income childless adults at 18%–138% FPL are generally not Medicaid-eligible in Alabama. This is a separate question from GLP-1 coverage policy but is relevant to the population that could hypothetically benefit from coverage expansion.
2. Non-expansion does not determine GLP-1 coverage. Tennessee (Anchor #13) and Wisconsin (Anchor #19) are both non-expansion states — TennCare expanded to positive GLP-1 obesity coverage in 2025, and ForwardHealth covers GLP-1s for weight loss. Alabama’s exclusion is an Ala. Admin. Code r. 560-X-16-.01(2)(b) regulatory decision, not a consequence of non-expansion status.

The structural mismatch between obesity prevalence and coverage is quantifiable. Per the CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023:

39.2% of Alabama’s adult population was obese in 2023 — the fifth-highest percentage in the nation.

Per America’s Health Rankings (AHR) 2024 Annual Report (cross-verified 2026-05-10): Alabama adults have a body mass index of 30.0 or higher at a rate of 38.9%, ranked 45th among states (tied with Arkansas). Both figures — BRFSS 2023 and AHR 2024 — reflect different reporting years and survey instruments; the directional conclusion is consistent: Alabama has one of the highest adult obesity prevalence rates in the nation.

Alabama’s combination of high obesity prevalence, non- expansion status, and categorical GLP-1 coverage exclusion creates a structural access gap: Alabamians with obesity who are Medicaid- eligible (elderly, disabled, SSI-eligible) face a non-coverage policy for their primary chronic disease burden, while Alabamians who might benefit from Medicaid expansion are not eligible for the program at all. This population — excluded from Medicaid GLP-1 coverage and without employer plan coverage — is the core cash-pay compounded GLP-1 demand pool.

Alabama in context — the 23-state taxonomy

The 23-state taxonomy as of 2026-05-10, with Alabama as the most recent addition:

Excluded populations and coverage non-paths

Several population categories and drug scenarios do NOT have a verified GLP-1 coverage pathway in Alabama Medicaid:

• Adults with obesity seeking chronic weight management: No coverage pathway. Ala. Admin. Code r. 560-X-16-.01(2)(b) categorical exclusion applies.
• Saxenda, Qsymia, Contrave, phentermine, orlistat: Not enumerated on the AMA PDL and not addressed in the PA Form 369 for any indication. No coverage pathway.
• Wegovy for MASH (non-alcoholic steatohepatitis/NASH): NOT verified in Alabama Medicaid primary sources. Alabama’s PA Form 369 Cardiac Agents Wegovy criteria specify only the MACE indication. Unlike California (Anchor #2) and Kentucky (Anchor #21), Alabama’s Wegovy pathway does not include a MASH carve-out in the verified PA Form 369 text.
• Pediatric and EPSDT: No Alabama-specific EPSDT GLP-1 bulletin was identified in the primary sources reviewed for this analysis. Unlike Indiana (Anchor #16, which has BT2023148 pediatric carve-in), Alabama has no verified EPSDT- specific GLP-1 policy. Federal EPSDT mandates (42 U.S.C.  § 1396d(r)) apply generally through the Patient 1st program, but the scope of GLP-1 coverage under EPSDT for Alabama patients under 21 is not verified in this analysis.
• ALL Kids (Alabama CHIP): ALL Kids is a separately administered program (Alabama Department of Public Health, through Blue Cross Blue Shield of Alabama) and is not coextensive with AMA Medicaid policy. ALL Kids GLP-1 coverage policy was not independently verified for this analysis.
• 1115 waiver: Alabama has no active or pending Section 1115 demonstration waiver with GLP-1 implications. Alabama Medicaid’s Community Waiver Program and Plan First 1115 waivers have no GLP-1 coverage provisions.

Patient action steps and appeal pathway

For Alabama Medicaid patients with a provider who has identified a qualifying indication (Zepbound for OSA, or Wegovy for established cardiovascular disease), the operational pathway is:

1. Verify your Medicaid plan type and coverage year. Alabama Medicaid is statewide FFS — there are no plan-level variations. The PDL and PA criteria described in this article apply uniformly. Confirm your Alabama Medicaid ID card and current enrollment status at the AMA Provider Assistance Center: 1-800-688-7989.
2. Confirm the PA pathway with your prescriber. For Zepbound OSA: the PA Form 369 Antidiabetic Agents/Incretin Mimetics section. For Wegovy MACE: the PA Form 369 Cardiac Agents section. PA forms are at medicaid.alabama.gov/content/9.0_Resources/9.4_Forms_Library/ 9.4.13_Pharmacy_Forms.aspx. Electronic PA submission is available via the Acentra Health portal at almedicaid.acentra.com.
3. Document the required clinical criteria before submission. For Zepbound OSA: sleep study confirming AHI ≥ 15, BMI measurement ≥ 30, age ≥ 18, documentation of no diabetes diagnosis, counseling on diet and physical activity. For Wegovy MACE: documented established cardiovascular disease (prior MI, stroke, or PAD), obesity or overweight documentation, and cardiovascular risk-benefit documentation.
4. Submit the PA request to Acentra Health. Mail or fax: P.O. Box 3570, Auburn, AL 36831 / Fax: 1-800-748-0116 / Phone: 1-800-748-0130. Electronic PA through the Acentra portal is available for Incretin Mimetics (Zepbound OSA). Verbal PA may be accepted for requests meeting prior-usage requirements.
5. If denied: submit additional medical justification. The prescriber may submit a written letter of medical justification with the PA Form 369 to Acentra Health. “Staff physicians will review this information” (per the December 8, 2025 AMA Provider ALERT). This is functionally a first-level reconsideration and may resolve some denials without a formal hearing.
6. If the PA denial stands: file a Fair Hearing request within 60 days. Alabama Medicaid fair hearings run under Ala. Admin. Code Chapter 560-X-3. The written appeal must be filed with the Alabama Medicaid Agency Hearings Office within 60 days of the initial determination. The hearing is held before an Administrative Law Judge (ALJ). The ALJ issues a recommended decision forwarded to the AMA Commissioner, who makes the final decision and is not bound by the ALJ’s recommendation. Judicial review under the Alabama APA (Ala. Code §§ 41-22-1 et seq.) is available only after the Commissioner’s final order.

Note on the 60-day deadline: The standard 560-X-3 deadline is 60 days from the initial determination. Whether pharmacy-claim-specific denials follow a different deadline was not separately verified; patients should confirm the applicable deadline at the time of denial with the AMA Hearings Office and consider consulting Legal Services Alabama or the Alabama Disabilities Advocacy Program for representation.

Related research

• Texas Medicaid GLP-1 coverage (2026): Pattern #1 — explicit non-coverage by Acentra PDL absence — Alabama’s closest structural analog in the series. Both states use Acentra Health as the pharmacy administrative services contractor and operate statewide FFS with no MCO pharmacy carve-out. The key divergence: Alabama’s April 1, 2026 PDL lists Zepbound with an OSA-only footnote restriction and has an explicit Wegovy MACE Cardiac Agents PA pathway; Texas’s Acentra January 30, 2026 PDL omits Zepbound entirely and has no Wegovy MACE pathway. Both states exclude chronic-weight-management coverage.
• Kentucky Medicaid GLP-1 coverage (2026): Pattern #21 — nullified-amendment exclusion + OSA Zepbound + MACE Wegovy via stand-alone PA PDFs — Kentucky and Alabama both have OSA-only Zepbound and MACE-only Wegovy carve-outs, but the operational architecture is inverted: Alabama’s Zepbound OSA carve-out is in the PDL drug class table (footnote ^); Kentucky’s is in stand-alone PA criteria PDFs on the MedImpact portal. Alabama does not require CPAP trial-and-failure or sleep specialist consultation; Kentucky requires both. Alabama uses Acentra Health; Kentucky uses MedImpact.
• GLP-1 pricing index: compounded semaglutide and tirzepatide market rates across 100+ providers — Alabama combines categorical GLP-1 weight-loss exclusion, non-expansion Medicaid status, and the 5th-highest adult obesity prevalence rate in the nation (39.2%, CDC BRFSS 2023). That structural triple — no Medicaid coverage, no Medicaid expansion, and a high-obesity population — produces a substantial cash-pay demand pool. The pricing index tracks current market rates for compounded semaglutide and tirzepatide across the full provider range, relevant for Alabama Medicaid-excluded patients evaluating cash-pay options.
• Oklahoma Medicaid GLP-1 coverage (2026): Pattern #24 — triple-carve-out state (Wegovy CV + MASH, Zepbound OSA, Imcivree monogenic-obesity) with OU College of Pharmacy PA — Oklahoma is Alabama’s closest analog in the categorical-exclusion cluster but extends to four DUR-Board- approved carve-outs vs. Alabama’s two. Both have Zepbound OSA and Wegovy MACE/CV carve-outs; Oklahoma adds Wegovy MASH and Imcivree monogenic-obesity (unique in the 24-state series). The structural divergence: Alabama uses Acentra Health (national PBM) and is a non-expansion state; Oklahoma uses OU College of Pharmacy / PMC (university-administered PA) and expanded via SQ 802 (July 2021). The 7.8% June 2025 SoonerCare FFS approval rate documents the same structural barrier that Alabama’s categorical exclusion creates.
• State Medicaid GLP-1 coverage hub — all 24 verified states — the 50-state coverage tracker. Alabama is Pattern #23 (PDL-enumerated OSA-only Zepbound carve-out + off-PDL Cardiac- criteria Wegovy MACE exclusion). The hub documents the full taxonomy across positive-coverage states (TN, NC, WI, MN, MO), indication-anchored states (WA, OH, CA, MI, MD), and explicit non-coverage states (TX, IL, NJ, NY, AZ, PA, IN, AL, KY, OK).

Sources and last-verified date

Last verified: 2026-05-10. Alabama Medicaid PDL updates quarterly; the next anticipated update is July 1, 2026. PA Form 369 criteria update on an as-needed basis. Readers should verify current PDL status at medicaid.alabama.gov and current PA criteria at the Acentra Health portal (almedicaid.acentra.com) before making any coverage determination.

1. Ala. Admin. Code r. 560-X-16-.01 — Alabama Medicaid Agency Administrative Code Chapter 16 “Pharmaceutical Services” (direct PDF: medicaid.alabama.gov/.../9.2_Adm_Code_Chap_16_Pharmaceutical_Services_7-15-24.pdf; verified 2026-05-10).
2. Alabama Medicaid Agency Preferred Drug List by Therapeutic Category, effective 04/01/2026 (direct PDF: medicaid.alabama.gov/.../4.3.7_PDL_Thera_3-16-26.pdf; verified 2026-05-10).
3. Alabama Medicaid Agency Preferred Drug List (Alphabetical), effective 04/01/2026 (direct PDF: medicaid.alabama.gov/.../4.3.7_PDL_Alpha_3-16-26.pdf; verified 2026-05-10).
4. Alabama Medicaid Preferred Drug and Prior Authorization Program, PA Form 369 Criteria Instructions, effective 08/15/2025 (direct PDF: medicaid.alabama.gov/.../9.4.14_PA_Form_369_Criteria_Instructions_8-15-25.pdf; Antidiabetic Agents/Incretin Mimetics section p. 21; Cardiac Agents section pp. 31–32; verified 2026-05-10).
5. Alabama Medicaid Agency Provider ALERT, “Preferred Drug List (PDL) and Pharmacy Quarterly Update,” dated December 8, 2025 (URL: medicaid.alabama.gov/alert_detail.aspx?ID=16674; verified 2026-05-10).
6. Alabama Medicaid Agency Provider ALERT, “Preferred Drug List (PDL) and Pharmacy Quarterly Update,” dated March 5, 2026 (direct PDF: medicaid.alabama.gov/.../1.0_ALERT_Preferred_Drug_List_Pharmacy_Quarterly_Update_3-5-26.pdf; verified 2026-05-10).
7. Alabama Medicaid Pharmacist, Spring 2025 (Acentra Health quarterly newsletter) (URL: almedicaid.acentra.com/.../Newsletter_Spring_2025.pdf; verified 2026-05-10).
8. 42 U.S.C. § 1396r-8(d)(2)(A) — federal optional weight-loss-drug exclusion authority (Cornell Law US Code mirror; verified 2026-05-10).
9. Alabama HJR162, 2026 Regular Session — House Joint Resolution; passed House March 5, 2026 (LegiScan summary; direct LegiScan fetch returned 403; secondary-source confirmation 2026-05-10).
10. Alabama SJR60, 2026 Regular Session — Senate Joint Resolution; introduced February 25, 2026; pending Senate Rules Committee (LegiScan summary; verified 2026-05-10).
11. Alabama Daily News, “Alabama task force grapples with high costs of weight-loss drugs amid rising obesity rates,” December 5, 2024 — verbatim Oliver + Ashmore + Embrey quotes (verified 2026-05-10 via WebFetch).
12. Alabama Daily News, “Alabama Medicaid Commissioner tapped for SEIB CEO amid increasing health cost concerns,” June 18, 2025 — verbatim Azar + Ivey quotes (verified 2026-05-10 via WebFetch).
13. Alabama Reflector, “Obesity requires comprehensive care, specialist tells Alabama task force,” November 17, 2025 — Dr. Saunders task-force testimony summary (verified 2026-05-10 via WebSearch; direct Cloudflare-403 on WebFetch).
14. KFF, “Medicaid Coverage of and Spending on GLP-1s,” January 16, 2026 — secondary classification anchor; Alabama is NOT among the 13 coverage states (verified 2026-05-10 via WebFetch).
15. CDC BRFSS 2023 / America’s Health Rankings 2024 Annual Report — Alabama 39.2% (BRFSS 2023) / 38.9% (AHR 2024) adult obesity prevalence (verified 2026-05-10 via WebFetch).